Pricing Log in Create free account

CytoMed Therapeutics Limited (GDTC) vs Phio Pharmaceuticals Corp. (PHIO)

CytoMed Therapeutics Limited and Phio Pharmaceuticals Corp. are both Biotechnology companies. CytoMed Therapeutics Limited is the larger, with a market value of $10.4M against $9.3M — 1.1× the size. Across the 9 metrics below, CytoMed Therapeutics Limited leads on 6 and Phio Pharmaceuticals Corp. on 3.

Valuation

Metric GDTC PHIO Biotechnology median
P/E n/m n/m 10.26
P/S n/m 68.34 9.18
P/B 0.55 0.74 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m 0.26 0.65
EV/Sales n/m (25.52) 8.98
Earnings yield (32.94%) (174.15%) (34.89%)
Free cash flow yield (0.40%) (131.34%) (24.52%)

Profitability

Metric GDTC PHIO Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin — 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (113.71%) (50.12%)
Return on assets 0.00% (100.78%) (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GDTC PHIO Biotechnology median
Revenue growth (TTM) — 78.95% 6.26%
EPS growth (last fiscal year) (68.75%) 84.03% 29.88%
Revenue growth, 5-year CAGR — (21.62%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GDTC PHIO Biotechnology median
Debt to equity 80.30 0.00 0.00
Current ratio 2.64 8.39 4.89
Net debt to EBITDA 0.86 2.28 1.01

Dividend

Metric GDTC PHIO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GDTC PHIO Biotechnology median
Market cap 10.41m 9.30m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack